---
title: "JMCT's application for issuing shares to specific targets has been approved by the Shanghai Stock Exchange"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264015231.md"
description: "According to the Zhitong Finance APP, JMCT announced that on November 3, 2025, the company received the \"Exchange Review Opinions on the Issuance of Stocks by Inner Mongolia JMCT Co., Ltd. to Specific Objects\" issued by the Shanghai Stock Exchange, which believes that the company's application for issuing stocks to specific objects meets the issuance conditions, listing conditions, and information disclosure requirements. The Shanghai Stock Exchange will submit the company's application documents to the China Securities Regulatory Commission for registration upon receipt"
datetime: "2025-11-03T12:03:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264015231.md)
  - [en](https://longbridge.com/en/news/264015231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264015231.md)
---

# JMCT's application for issuing shares to specific targets has been approved by the Shanghai Stock Exchange

According to the Zhitong Finance APP, JMCT (600844.SH) announced that on November 3, 2025, it received the "Review Opinions on the Issuance of Stocks by Inner Mongolia JMCT to Specific Objects" issued by the Shanghai Stock Exchange, which believes that the company's application for issuing stocks to specific objects meets the issuance conditions, listing conditions, and information disclosure requirements. The Shanghai Stock Exchange will submit the company's application documents to the China Securities Regulatory Commission for registration after receiving them

### Related Stocks

- [600844.CN](https://longbridge.com/en/quote/600844.CN.md)

## Related News & Research

- [Indonesia's Danantara will manage fund for important development projects, president says](https://longbridge.com/en/news/295912367.md)
- [SpaceX Stock Forecast: Musk Says AI Could Account for 99% of Valuation in Five Years, How Much Higher Can SPCX Stock Rise?](https://longbridge.com/en/news/295736725.md)
- [ZEAL: Advanced obesity pipeline and strong cash position despite lower revenue from milestone timing](https://longbridge.com/en/news/295745767.md)
- [Faeth Therapeutics wins FDA fast-track status for PIKTOR-paclitaxel in advanced endometrial cancer](https://longbridge.com/en/news/296098405.md)
- [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md)